Around the world, publicly-funded healthcare systems face a common challenge: ensuring limited resources are allocated to treatments offering the best value for patients and taxpayers. Without robust ...

We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

The technologies, which have been conditionally recommended in draft guidance, can help detect vertebral fragility fractures (VFFs) on medical images taken for unrelated condition. This means they ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

We’re updating the recommendations for drug treatments in our clinical guideline on the diagnosis and management of chronic heart failure first published in 2018. Clinical practice over the timing of ...

Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults. Last reviewed: ...

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. Last ...

NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines Optimisation and Chemotherapy Clinical Reference Groups (CRGs ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...